Amiloride in Primary progressive Multiple sclerosis

• Research type

  Research Study

• Full title

  Amiloride Treatment in Primary progressive Multiple Sclerosis

• Sponsor organisation

  Oxford Radcliffe NHS Trust.

• Eudract number

  2007-004051-11

• ISRCTN Number

  N/A

• Research summary

  The primary objective of the study is to evaluate the effects of the drug, oral amiloride in primary progressive Multiple Sclerosis (MS) patients during 12 months of treatment. This project aims to evaluate the effect of oral amiloride using Magnetic resonance imaging (brain scans).Participants will be drawn from those who previously completed the one year MRI study on primary progressive MS patients on specific treatment. Participants from that study will continue on to this present study. Participants will be given oral amiloride at a dose of 10mg a day daily for a period of 52 weeks. All participants will be followed up for one year, undergoing 4 MRI scans. The participants will attend clinic visits at the same time for clinical outcomes and have 20ml of blood collected and urine sample at each visit.

• REC name

  South Central - Oxford A Research Ethics Committee

• REC reference

  08/H0604/155

• Date of REC Opinion

  18 Dec 2008

• REC opinion

  Further Information Favourable Opinion